SCHEMBL5166006

SCHEMBL5166006

CSc1nccc(-c2[nH]c(-c3ccc(C(N)=O)cc3)nc2-c2ccc3c(c2)OCO3)n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 15/20 0.70
CSNK1D P48730 4/20 0.70
CSNK1A1 P48729 2/20 0.70
CSNK1E P49674 2/20 0.70
ACVR1B P36896 2/20 0.70
KDM4E B2RXH2 1/20 0.70
RIPK2 O43353 1/20 0.70
PRKD3 O94806 1/20 0.70
ALDH1A1 P00352 1/20 0.70
CYP1A2 P05177 1/20 0.70
CYP3A4 P08684 1/20 0.70
CYP2D6 P10635 1/20 0.70
MAPT P10636 1/20 0.70
HPGD P15428 1/20 0.70
MAPK1 P28482 1/20 0.70
CYP2C19 P33261 1/20 0.70
TGFBR2 P37173 1/20 0.70
RPS6KA1 Q15418 1/20 0.70
CSNK1A1L Q8N752 1/20 0.70
HSD17B10 Q99714 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137950 0.84 TGFBR1 (0.69) TGFBR1CSNK1DCSNK1A1CSNK1EACVR1B
SCHEMBL5497694 0.83 TGFBR1 (0.75) TGFBR1CSNK1DCSNK1A1CSNK1EACVR1B
Sb-431542 SCHEMBL29381798 0.82 TGFBR1 (1.00) TGFBR1CSNK1DCSNK1A1CSNK1EACVR1B
Sb-431542 SCHEMBL29359059 0.82 TGFBR1 (1.00) TGFBR1CSNK1DCSNK1A1CSNK1EACVR1B
Sb-431542 SCHEMBL310028 0.82 TGFBR1 (1.00) TGFBR1CSNK1DCSNK1A1CSNK1EACVR1B
Sb-431542 SCHEMBL2681356 0.81 TGFBR1 (0.98) TGFBR1CSNK1DCSNK1A1CSNK1EACVR1B
Sb-431542 SCHEMBL29432843 0.81 TGFBR1 (0.98) TGFBR1CSNK1DCSNK1A1CSNK1EACVR1B
Sb-431542 SCHEMBL155156 0.77 TGFBR1 (0.85) TGFBR1CSNK1DCSNK1A1CSNK1EACVR1B
SCHEMBL373737 0.77 TGFBR1 (1.00) TGFBR1CSNK1DCSNK1A1CSNK1EACVR1B
SCHEMBL29362480 0.77 TGFBR1 (1.00) TGFBR1CSNK1DCSNK1A1CSNK1EACVR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1804801-A2 METHODS OF TREATING VASCULAR INJURIES Biogen Idec MA, Inc. (US) 2007-07-11 EP claimed
WO-2006044509-A2 METHODS OF TREATING VASCULAR INJURIES BIOGEN IDEC MA INC. (US) 2006-04-27 WO claimed
WO-2008013928-A2 TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR BIOGEN IDEC MA INC. (US) 2008-01-31 WO disclosed
EP-1804801-A2 METHODS OF TREATING VASCULAR INJURIES Biogen Idec MA, Inc. (US) 2007-07-11 EP disclosed
EP-1786802-A1 PYRIMIDINYLIMIDAZOLES AS TGF-BETA INHIBITORS Biogen Idec MA, Inc. (US) 2007-05-23 EP disclosed
WO-2006044509-A2 METHODS OF TREATING VASCULAR INJURIES BIOGEN IDEC MA INC. (US) 2006-04-27 WO disclosed
WO-2006026306-A1 PYRIMIDINYLIMIDAZOLES AS TGF-BETA INHIBITORS BIOGEN IDEC MA INC. (US) 2006-03-09 WO disclosed